Prospective randomized trial of azathioprine in cryopreserved valved allografts in children

Area of Science:

• Pediatric cardiology
• Immunology
• Transplantation immunology

Background:

• Congenital heart defects often require surgical repair using allografts.
• Cryopreserved valved allografts are utilized in pediatric cardiac surgery.
• Understanding the impact of immunosuppression on allograft outcomes is crucial.

Purpose of the Study:

• To prospectively evaluate azathioprine's effect on humoral immune response to HLA alloantigens.
• To assess azathioprine's impact on the function of cryopreserved valved allografts in pediatric recipients.
• To determine if azathioprine influences antibody production and allograft performance.

Main Methods:

• A randomized controlled trial involving 13 children receiving cryopreserved valved allografts.
• Administration of azathioprine (4 mg/kg intraoperatively, then 2.0 +/- 0.5 mg/kg daily for 3 months) versus a control group.
• Measurement of panel reactive antibodies against HLA class I and II antigens pre- and post-operation (1 and 3 months).

Main Results:

• No significant difference in panel reactive antibodies between azathioprine and control groups at 1 and 3 months post-operation.
• Similar levels of allograft valve stenosis and insufficiency were observed in both groups.
• Humoral immune response to HLA alloantigens was not significantly altered by azathioprine treatment.

Conclusions:

• Azathioprine does not significantly reduce the immune response to HLA alloantigens in children receiving cryopreserved valved allografts.
• Azathioprine treatment did not adversely affect the function or lead to increased stenosis/insufficiency in these allografts.
• The findings suggest azathioprine may not be beneficial for modulating immune responses in this specific pediatric allograft setting.